DSM-Firmenich Q1 Results Beat Estimates on Strong Growth

Key Performance Highlights

DSM-Firmenich AG reported strong first-quarter 2026 results, surpassing analyst expectations with a 4% organic sales growth against a forecasted 1.6%. The company posted an adjusted EBITDA of €434 million, slightly ahead of the €428 million estimate.

Group sales reached €2,276 million for the quarter. This performance was driven by a 4% increase in volume, while pricing remained flat. However, foreign exchange impacts negatively affected sales by 6%.

Divisional Performance Breakdown

The Perfumery & Beauty division led the growth with sales of €967 million, an 8% organic increase. This was largely supported by strong double-digit growth in fine fragrance. The division saw a particularly strong performance in March as customers advanced orders.

The Taste, Texture & Health division generated €791 million in sales, achieving 2% organic growth despite soft market conditions. Solid performance in Europe and North America offset softness in Asia and Latin America.

The Health, Nutrition & Care division reported sales of €497 million, reflecting 4% organic growth. The segment's adjusted EBITDA grew 6% from estimates, with notable performance in early life nutrition.

Outlook and Corporate Actions

The company confirmed its full-year 2026 guidance. It continues to expect organic sales growth between 2% and 4% with an adjusted EBITDA margin of approximately 20%. This signals confidence in its business strategy for the remainder of the year.

Furthermore, DSM-Firmenich announced a significant corporate development. The company will establish a dual listing on the SIX Swiss Exchange, which is expected to become effective on May 21, 2026.

Summary and Forward Look

DSM-Firmenich has demonstrated a robust start to 2026, with key financial metrics exceeding market consensus. The company's ability to drive volume growth across its core divisions is a positive signal. Investors will be monitoring the impact of the new dual listing and the company's performance in navigating regional market softness moving forward.

FAQ

Q: What were the key drivers of DSM-Firmenich's Q1 growth?
A: The primary drivers were 4% group-wide volume growth and a particularly strong performance in the Perfumery & Beauty division, which saw 8% organic growth led by fine fragrance.

Q: Did DSM-Firmenich change its full-year guidance?
A: No, the company maintained its full-year 2026 guidance for 2% to 4% organic sales growth and an adjusted EBITDA margin of approximately 20%.

Source: Investing.com